Stockscreener 앱 받기
2.06
0.96%
-0.02
시간 외 거래:
2.10
0.04
+1.94%
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
MBRX Expects Cash Reserves to Fund Operations Through Q3 2026 - GuruFocus
Optimism Surrounds Moleculin's (MBRX) MIRACLE Trial Progress - GuruFocus
Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks
Moleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AML - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event | MBRX SEC FilingForm 8-K - Stock Titan
Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView
Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan
Moleculin Biotech 2025 Annual Report: Annamycin Clinical Trials & Pipeline Update - Minichart
Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView
Moleculin Biotech (NASDAQ: MBRX) outlines Annamycin Phase 3 AML strategy - Stock Titan
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Moleculin leaders set for March 24 ROTH healthcare investor chat - Stock Titan
Moleculin Biotech Inc expected to post a loss of $6.11 a shareEarnings Preview - TradingView
Net current asset value per share of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
Moleculin Reports Second Quarter 2024 Financial Results and Prov - GuruFocus
MBRX Should I Buy - Intellectia AI
Moleculin Biotech releases CEO update on leukemia trial By Investing.com - Investing.com India
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - The Manila Times
Moleculin Biotech releases CEO update on leukemia trial - Investing.com
Leukemia trial update: Moleculin CEO explains MIRACLE drug study - Stock Titan
Moleculin Biotech (MBRX) seeks vote on 6.37M warrants and name change - Stock Titan
Pullback Watch: Will Moleculin Biotech Inc benefit from geopolitical trendsMarket Activity Report & Safe Capital Growth Tips - baoquankhu1.vn
Moleculin Announces Closing of up to $16.5 Million Public Offering - Quantisnow
Aug Reactions: Will Moleculin Biotech Inc benefit from geopolitical trends2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
MBRX PE Ratio & Valuation, Is MBRX Overvalued - Intellectia AI
Moleculin Biotech (MBRX) seeks OK for 6.37M warrants, $15.3M proceeds - Stock Titan
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Moleculin Biotech Inc. forming higher highs and higher lowsJuly 2025 Reactions & Community Trade Idea Sharing Platform - mfd.ru
Moleculin Biotech Raises Capital via Inducement Warrant Agreements - TipRanks
Why Moleculin Biotech Inc. stock remains on buy listsDollar Strength & Daily Entry Point Trade Alerts - mfd.ru
Moleculin Biotech Secures Up To $8.3 Million Via Warrant Exercise; Issues 300% Series H Warrants - TradingView
Moleculin Biotech Exercises Warrants for $8.3M - Intellectia AI
Moleculin Biotech raises $8.3 million through warrant exercise By Investing.com - Investing.com Canada
Moleculin shares slide sharply after warrant exercise deal - MSN
Aug Intraday: Can Moleculin Biotech Inc maintain sales growth2025 Price Momentum & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Moleculin Stock Plunges On $8.3 Million Warrant Exercise - Nasdaq
Moleculin Biotech stock plunges after warrant exercise agreement By Investing.com - Investing.com Nigeria
Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com South Africa
Moleculin Biotech raises $8.3 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Agreement for Immediate Exercise of Warrants to Raise Approximately $8.3 Million - Quiver Quantitative
Moleculin reports promising early data in pivotal AML treatment trial By Investing.com - Investing.com India
Moleculin Biotech Issues New Investor Corporate Presentation - TipRanks
Moleculin Biotech (MBRX) Nears Key Milestone in Leukemia Trial P - GuruFocus
Moleculin Biotech stock rises as AML drug trial shows promising results - Investing.com Nigeria
1.20%
0.06%
자본화:
|
볼륨(24시간):